Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
11 juin 2024 09h00 HE
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 16h05 HE
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers
02 mars 2022 08h37 HE
|
Hillstream BioPharma Inc.
HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomasHSB-1216 was recently granted Orphan Drug Designation to treat Uveal Melanoma by the...
Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
15 sept. 2021 16h01 HE
|
Crinetics Pharmaceuticals, Inc.
CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in...
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
06 nov. 2020 08h31 HE
|
Crinetics Pharmaceuticals, Inc.
Reported positive topline results for the ACROBAT Edge and Evolve Phase 2 trials of oral paltusotine for the treatment of acromegaly CRN04777 received Rare Pediatric Disease Designation for the...
Cerecin Announces Orphan Drug Designation from U.S. FDA for Tricaprilin in the Treatment of Infantile Spasms
29 oct. 2020 08h00 HE
|
Cerecin
SINGAPORE AND DENVER, COLORADO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on discovering and developing brain therapeutics, announced today that the U.S. Food...
U.S. FDA Grants Rare Pediatric Disease Designation to Cerecin’s Investigational Drug Tricaprilin for the Treatment of Infantile Spasms
08 oct. 2020 04h48 HE
|
Cerecin
SINGAPORE AND DENVER, COLORADO , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on discovering and developing brain therapeutics, announced that the U.S. Food and...